133 related articles for article (PubMed ID: 33413022)
1. Pharmacokinetics, metabolism, and excretion of licogliflozin, a dual inhibitor of SGLT1/2, in rats, dogs, and humans.
Wang-Lakshman L; Mendonza AE; Huber R; Walles M; He Y; Jarugula V
Xenobiotica; 2021 Apr; 51(4):413-426. PubMed ID: 33413022
[TBL] [Abstract][Full Text] [Related]
2. The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes.
He YL; Haynes W; Meyers CD; Amer A; Zhang Y; Mahling P; Mendonza AE; Ma S; Chutkow W; Bachman E
Diabetes Obes Metab; 2019 Jun; 21(6):1311-1321. PubMed ID: 30724002
[TBL] [Abstract][Full Text] [Related]
3. Preclinical metabolism and disposition of luseogliflozin, a novel antihyperglycemic agent.
Hasegawa M; Chino Y; Horiuchi N; Hachiuma K; Ishida M; Fukasawa Y; Nakai Y; Yamaguchi J
Xenobiotica; 2015; 45(12):1105-15. PubMed ID: 26489961
[TBL] [Abstract][Full Text] [Related]
4. Absorption, distribution, metabolism, and excretion of mTOR kinase inhibitor CC-223 in rats, dogs, and humans.
Tong Z; Atsriku C; Yerramilli U; Wang X; Nissel J; Li Y; Surapaneni S
Xenobiotica; 2019 Jan; 49(1):43-53. PubMed ID: 29206565
[TBL] [Abstract][Full Text] [Related]
5. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans.
Weinz C; Schwarz T; Kubitza D; Mueck W; Lang D
Drug Metab Dispos; 2009 May; 37(5):1056-64. PubMed ID: 19196845
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of NS-105, a novel cognition enhancer. 1st communication: absorption, metabolism and excretion in rats, dogs and monkeys after single administration of 14C-NS-105.
Mukai H; Sugimoto T; Ago M; Morino A
Arzneimittelforschung; 1999 Nov; 49(11):881-90. PubMed ID: 10604039
[TBL] [Abstract][Full Text] [Related]
7. Metabolism and excretion of RWJ-333369 [1,2-ethanediol, 1-(2-chlorophenyl)-, 2-carbamate, (S)-] in mice, rats, rabbits, and dogs.
Mamidi RN; Mannens G; Annaert P; Hendrickx J; Goris I; Bockx M; Janssen CG; Kao M; Kelley MF; Meuldermans W
Drug Metab Dispos; 2007 Apr; 35(4):566-75. PubMed ID: 17220243
[TBL] [Abstract][Full Text] [Related]
8. Licogliflozin, a Novel SGLT1 and 2 Inhibitor: Body Weight Effects in a Randomized Trial in Adults with Overweight or Obesity.
Bays HE; Kozlovski P; Shao Q; Proot P; Keefe D
Obesity (Silver Spring); 2020 May; 28(5):870-881. PubMed ID: 32187881
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and metabolism of the new thromboxane A2 receptor antagonist ramatroban in animals. 1st communication: absorption, concentrations in plasma, metabolism, and excretion after single administration to rats and dogs.
Boberg M; Ahr HJ; Beckermann B; Bühner K; Siefert HM; Steinke W; Wünsche C; Hirayama M
Arzneimittelforschung; 1997 Aug; 47(8):928-38. PubMed ID: 9296279
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects.
Miao Z; Nucci G; Amin N; Sharma R; Mascitti V; Tugnait M; Vaz AD; Callegari E; Kalgutkar AS
Drug Metab Dispos; 2013 Feb; 41(2):445-56. PubMed ID: 23169609
[TBL] [Abstract][Full Text] [Related]
11. Glucosuric, renal and haemodynamic effects of licogliflozin, a dual inhibitor of sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2, in patients with chronic kidney disease: A randomized trial.
He Y; Pachori A; Chen P; Ma S; Mendonza AE; Amer A; Marbury TC; Hinder M
Diabetes Obes Metab; 2021 May; 23(5):1182-1190. PubMed ID: 33512754
[TBL] [Abstract][Full Text] [Related]
12. Absorption, Metabolism, and Excretion of Taselisib (GDC-0032), a Potent
Ma S; Cho S; Sahasranaman S; Zhao W; Pang J; Ding X; Dean B; Wang B; Hsu JY; Ware J; Salphati L
Drug Metab Dispos; 2023 Apr; 51(4):436-450. PubMed ID: 36623882
[TBL] [Abstract][Full Text] [Related]
13. Metabolism and disposition of [(14)C]tivantinib after oral administration to humans, dogs and rats.
Murai T; Takakusa H; Nakai D; Kamiyama E; Taira T; Kimura T; Jimbo T; Bathala M; Pickersgill F; Zahir H; Tokui T; Savage RE; Ashwell MA; Izumi T
Xenobiotica; 2014 Nov; 44(11):996-1008. PubMed ID: 24911380
[TBL] [Abstract][Full Text] [Related]
14. Metabolism, excretion and pharmacokinetics of [
Lam JL; Vaz A; Hee B; Liang Y; Yang X; Shaik MN
Xenobiotica; 2017 Dec; 47(12):1064-1076. PubMed ID: 27866461
[TBL] [Abstract][Full Text] [Related]
15. Absorption, Distribution, Metabolism, and Excretion of [
James AD; Kulmatycki K; Poller B; Romeo AA; Van Lier JJ; Klein K; Pearson D
Drug Metab Dispos; 2023 Jul; 51(7):873-883. PubMed ID: 37308298
[TBL] [Abstract][Full Text] [Related]
16. Biotransformation of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, in Dogs, Rats, and Humans, In Vivo and In Vitro.
Gerisch M; Heinig R; Engelen A; Lang D; Kolkhof P; Radtke M; Platzek J; Lovis K; Rohde G; Schwarz T
Drug Metab Dispos; 2018 Nov; 46(11):1546-1555. PubMed ID: 30171161
[TBL] [Abstract][Full Text] [Related]
17. Metabolism and disposition in rats, dogs, and humans of erdafitinib, an orally administered potent pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor.
Scheers E; Borgmans C; Keung C; Bohets H; Wynant I; Poggesi I; Cuyckens F; Leclercq L; Mamidi RNVS
Xenobiotica; 2021 Feb; 51(2):177-193. PubMed ID: 32902324
[TBL] [Abstract][Full Text] [Related]
18. Absorption, distribution, metabolism, and excretion of [¹⁴C]GDC-0449 (vismodegib), an orally active hedgehog pathway inhibitor, in rats and dogs: a unique metabolic pathway via pyridine ring opening.
Yue Q; Chen YH; Mulder T; Deese A; Takahashi R; Rudewicz PJ; Reynolds M; Solon E; Hop CE; Wong H; Khojasteh SC
Drug Metab Dispos; 2011 Jun; 39(6):952-65. PubMed ID: 21363998
[TBL] [Abstract][Full Text] [Related]
19. Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs.
Yamaguchi T; Nakajima Y; Mizobuchi M; Inazawa K; Kanazu T; Kadono K; Ohkawa T; Iwatani K
Arzneimittelforschung; 1998 Oct; 48(10):995-1006. PubMed ID: 9825117
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and mass balance of vericiguat in rats and dogs and distribution in rats.
Janssen W; Schwarz T; Bütehorn U; Steinke W; Sandmann S; Lang D; Kern A; Hucke F; Gerisch M
Xenobiotica; 2022 May; 52(5):453-462. PubMed ID: 35616579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
